About Rampart Bioscience
Rampart Bioscience is a company based in La Jolla (United States) founded in 2020 by Louis Breton and Jeffrey Bartlett.. Rampart Bioscience has raised $85 million across 1 funding round from investors including Orbimed, RA Capital and Forbion. The company has 32 employees as of December 31, 2022. Rampart Bioscience operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter La Jolla, United States
- Employees 32 as on 31 Dec, 2022
- Founders Louis Breton, Jeffrey Bartlett
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rampart Bioscience, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$85 M (USD)
in 1 rounds
-
Latest Funding Round
$85 M (USD), Series A
Oct 24, 2023
-
Investors
Orbimed
& 3 more
-
Employee Count
32
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Rampart Bioscience
Rampart Bioscience has successfully raised a total of $85M through 1 strategic funding round. The most recent funding activity was a Series A round of $85 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $85.0M
-
First Round
First Round
(24 Oct 2023)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series A - Rampart Bioscience | Valuation | Forbion |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Rampart Bioscience
Rampart Bioscience has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Forbion. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rampart Bioscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Rampart Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rampart Bioscience Comparisons
Competitors of Rampart Bioscience
Rampart Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rampart Bioscience
Frequently Asked Questions about Rampart Bioscience
When was Rampart Bioscience founded?
Rampart Bioscience was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Where is Rampart Bioscience located?
Rampart Bioscience is headquartered in La Jolla, United States. It is registered at La Jolla, California, United States.
Who is the current CEO of Rampart Bioscience?
Louis Breton is the current CEO of Rampart Bioscience. They have also founded this company.
Is Rampart Bioscience a funded company?
Rampart Bioscience is a funded company, having raised a total of $85M across 1 funding round to date. The company's 1st funding round was a Series A of $85M, raised on Oct 24, 2023.
How many employees does Rampart Bioscience have?
As of Dec 31, 2022, the latest employee count at Rampart Bioscience is 32.
What does Rampart Bioscience do?
Rampart Bioscience was founded in 2020 as a biotechnology company in La Jolla, United States. Gene-based therapies are researched and developed for metabolic disorders, with emphasis on gene delivery, protein sciences, and clinical translation. Non-viral methods are utilized to create optimized treatments. Drug development and disease management solutions are provided for hypophosphatasia and genetic liver diseases.
Who are the top competitors of Rampart Bioscience?
Rampart Bioscience's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are Rampart Bioscience's investors?
Rampart Bioscience has 4 investors. Key investors include Orbimed, RA Capital, Forbion, and Healthcap.